PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreatic cancer cell lines
Kai Wang, Huynh Nhi, Xiao Wang, Marina Pajic, Ashleigh Parkin, Jennifer Man, Graham S Baldwin, Mehrdad Nikfarjam, Hong He
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH | E-CENTURY PUBLISHING CORP | Published : 2019
BACKGROUND/OBJECTIVE: Pancreatic ductal adenocarcinoma (PDA) remains the most lethal malignancy due to lack of an effective treatment. P21-activated kinases (PAKs) play a key role not only in cell proliferation and migration, but also in mediating chemo-resistance in PDA. The aim of this study was to investigate the combined effect of a PAK inhibitor PF-3758309 with multiple chemotherapeutic reagents on a panel of patient-derived PDA cell lines, and potential mechanisms involved. METHODS: Cells were treated with PF-3758309 plus or minus gemcitabine, 5-fluorouracil (5-FU) or abraxane, and cell growth was determined using a cell proliferation assay kit. Protein expression profiles were measure..View full abstract
Awarded by Austin Medical Research Foundation
Awarded by National Health and Medical Research Council of Australia
This work was supported by the Austin Medical Research Foundation (HH, No. He007), the National Health and Medical Research Council of Australia (GSB, No. 1041831) and the Pancare Foundation (https://www.pancare.org.au). The authors would like to thank Dr. Dannel Yeo for his help and suggestion in TKCC cell culture. Dr. Kai Wang is supported by scholarships from the University of Melbourne and Pancare foundation (Moshe Sambor Scholarship).